论文信息 - Cancer Therapy : Preclinical Met Kinase Inhibitor E 7050 Reverses Three Different MechanismsofHepatocyteGrowth Factor – Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer - 字舞流文

Cancer Therapy : Preclinical Met Kinase Inhibitor E 7050 Reverses Three Different MechanismsofHepatocyteGrowth Factor – Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

T. Nakagawa | Wei Wang | N. Mukaida | S. Sone | S. Yano | Y. Nishioka | Kunio Matsumoto | S. Takeuchi | Tadaaki Yamada | T. Uenaka | Qi Li | Takahiro J. Nakamura | Hitomi Koizumi